OmniAb Q1 Earnings Call Highlights
OmniAb, Inc. (OABI) Reports Q1 Loss, Tops Revenue Estimates
OmniAb Reports First Quarter 2026 Financial Results and Business Highlights
OmniAb to Participate in Three Upcoming Investor Conferences
OmniAb to Report First Quarter 2026 Financial Results on May 7
Matthew Foehr Sells 19,244 Shares of OmniAb (NASDAQ:OABI) Stock
OmniAb, Inc. (OABI) Q4 2025 Earnings Call Transcript
OmniAb, Inc. (OABI) Reports Q4 Loss, Misses Revenue Estimates
OmniAb Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
OmniAb (OABI) Projected to Post Earnings on Wednesday
OmniAb to Report Fourth Quarter 2025 Financial Results on March 4
OmniAb, Inc. (OABI) Discusses Launch and Scientific Overview of OmniUltra Technology Platform Transcript
Launch of OmniUltra Expands OmniAb's Reach into New Markets and Applications, Advances Leadership in Antibody Discovery Technologies
OmniAb to Hold OmniUltra Virtual Investor Event on December 15
OmniAb Enters into a Technology License and Services Agreement for Antibody Discovery with a Newly-Formed Incubated Company of ArrowMark Partners and Viking Global Investors
OmniAb, Inc. (OABI) Q3 2025 Earnings Call Transcript
OmniAb, Inc. (OABI) Reports Q3 Loss, Misses Revenue Estimates
OmniAb Reports Third Quarter 2025 Financial Results and Business Highlights
OmniAb, Inc. (OABI) Expected to Beat Earnings Estimates: Should You Buy?
OmniAb to Participate in Three Investor Conferences in November
OmniAb to Report Third Quarter 2025 Financial Results on November 4
OmniAb Announces $30 Million Private Placement
OmniAb, Inc. (OABI) Q2 2025 Earnings Call Transcript
OmniAb, Inc. (OABI) Reports Q2 Loss, Lags Revenue Estimates
OmniAb Reports Second Quarter 2025 Financial Results and Business Highlights
OmniAb to Report Second Quarter 2025 Financial Results on August 6
OmniAb Showcases Innovative High-Throughput Single B-cell Screening xPloration® Platform at the 21st Annual PEGS Boston Summit
OmniAb, Inc. (OABI) Q1 2025 Earnings Call Transcript
OmniAb, Inc. (OABI) Reports Q1 Loss, Misses Revenue Estimates
OmniAb Reports First Quarter 2025 Financial Results and Business Highlights
VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program
OmniAb to Participate in Five Upcoming Investor Conferences
OmniAb Announces Two New Appointments to its Board of Directors
OmniAb, Inc. (OABI) Q4 2024 Earnings Call Transcript
OmniAb, Inc. (OABI) Reports Q4 Loss, Tops Revenue Estimates
OmniAb Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
OmniAb to Report Fourth Quarter 2024 Financial Results on March 18
OmniAb to Participate in Two Investor Conferences in March
Kuehn Law Encourages Investors of OmniAb, Inc. to Contact Law Firm
OmniAb Technologies Featured in Two Presentations at the 2024 Antibody Engineering & Therapeutics Conference
OmniAb, Inc. (OABI) Q3 2024 Earnings Call Transcript
OmniAb, Inc. (OABI) Reports Q3 Loss, Lags Revenue Estimates
OmniAb, Inc. (OABI) Q2 2024 Earnings Call Transcript
Long Assets On Path To Creating Significant Value, Shorting Remains Very Challenging
OmniAb Announces Publication of Scientific Paper on Heavy Chain-Only Single-Domain Antibody Chicken Platform in the Journal of Immunology
OmniAb to Participate in the Jefferies Global Healthcare Conference
OmniAb Presents High-Throughput Single B-cell Screening xPloration® Data at the 20th Annual PEGS Boston Summit
OmniAb, Inc. (OABI) Q1 2024 Earnings Call Transcript
OmniAb Reports First Quarter 2024 Financial Results and Business Highlights